An Open-Label Phase 2 Proof or Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471
Recruiting
17 years - 65 years
All
Phase
2
2 participants needed
1 Location
Brief description of study
This is an open-label study of 12 months of dosing with ACH-0144471. The study will enroll patients with biopsy-confirmed C3G or IC-MPGN who meet eligibility criteria for this study.
There will be a multi-step screening process. At the initial screening visit, all screening eligibility assessments, except the renal biopsy, will be performed. If the subject remains eligible based on the results from the initial screening visit, then arrangements can be made for renal biopsy and vaccinations. The initial screening visit must occur no more than 75 days before the first dose date. The renal biopsy must occur no more than 30 days before the first dose, but will be targeted to occur approximately two weeks prior to the first dose of ACH-0144471.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: C3,IC-MPGN
-
Age: 17 years - 65 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 830210
Find a site
,
Your Information has been sent successfully.
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up
Send a message
Enter your contact details to connect with study team
Primary Contact
Message For Non Enrolling By Invitation Trial
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or